Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206GlobeNewsWire • 05/17/21
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business UpdateGlobeNewsWire • 05/06/21
Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021GlobeNewsWire • 04/29/21
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/12/21
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business UpdateGlobeNewsWire • 03/11/21
Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 03/08/21
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021GlobeNewsWire • 03/03/21
Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 01/26/21
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBrGlobeNewsWire • 01/21/21
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial OfficerGlobeNewsWire • 12/17/20
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary DiseaseGlobeNewsWire • 12/10/20
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020GlobeNewsWire • 11/30/20
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)Insider Monkey • 10/26/20
Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract InfectionsGlobeNewsWire • 09/24/20
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute PyelonephritisGlobeNewsWire • 09/08/20